Silverback Therapeutics, Inc. announced Thilo Schroeder, Ph.D. will not stand for re-election as a member of the company's board of directors when his term as a class II director expires at the company's 2022 annual meeting of stockholders and on March 14, 2022, Dr. Schroeder resigned as a member of the audit committee of the board of directors of the company to focus on other endeavors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.08 USD | -3.92% |
|
-11.21% | +47.45% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.45% | 783M | |
+34.01% | 51.07B | |
+34.83% | 38.61B | |
-8.02% | 38.78B | |
-8.98% | 27.32B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- SPRY Stock
- News ARS Pharmaceuticals, Inc.
- Silverback Therapeutics, Inc. Announces Thilo Schroeder Will Not Stand for Re-Election as Member of the Company Board of Directors